Hemophilia

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Data Elements

DEMOGRAPHICS

Diagnosis
Age
Gender
Race / Ethnicity
BMI
Height / Weight

PT CHARACTERISTICS

Hemophilia Severity
IV Access Method
Target Joints
Prophylaxis vs. Breakthrough Bleeding Products
Inhibitor Use
Last Bleed Date
Number of Bleeds

PRIOR HISTORY

First Diagnosis of Hemophilia Date
Prior Regimen
Prior Treatment Status (new to therapy or refill)
Duration of Therapy
Reason for Switch

PT ADHERENCE

Current Therapy
Duration
Dose
Prophylaxis Product Use
Bleeding Product Use
% Doses Taken
% Doses Missed

PROVIDERS

Type (Physician, NP, PA)
Specialty
Academic vs Community
Specialty Pharmacy vs. Hemophilia Treatment Center

PAYERS

Type (Commercial, Medicare, Medicaid, Dual Eligible)
Payer Name
Self-Pay and Patient Assistance
Eligibility
Correct PA form
Denial Reason

PA TIMELINE

Copay Amount
PA Submitted Date
Approval / Denial Date
Appeals Submitted

DISPENSING INFO

Current Treatment Regimen Rx
Intended Regimen
Actual Regimen
Duration
Dispensed Regimen
Duration / Refills
Gaps in Therapy

Patient Tear Sheet

Real Time Aggregated Data is organized and visualized at a patient level for immediate and longitudinal insight.
Click on image below for a 3 page PDF of a Patient Tear Sheet.

Publications

2021

A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A

Shawn X. Sun, Andrew Frick

10.18553/jmcp.2021.27.4-a.s1

Poster Presented at: Academy of Managed Care Pharmacy (AMCP)

Conference dates: April 12, 2021 - April 16, 2021

A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice

Shawn X. Sun, Andrew Frick

DOI: 10.1111/hae.14236: ABS039

Poster Presented at: European Association for Haemophilia and Allied Disorders

Conference dates: February 3, 2021 - February 5, 2021

2020

Real-World Outcomes Before and After Switching From Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in The United States

Shawn X. Sun, Scott Milligan

Res Pract Thromb Haemost. 2020; 4 (Suppl 1)

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 12, 2020 - July 14, 2020

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States

Louis Aledort, MD; Scott Milligan, PhD; Maureen Watt, MSc; and Jason Booth, MPH

DOI: 10.18553/jmcp.2020.26.4.492

Manuscript Published in: Journal of Managed Care & Specialty Pharmacy

Date of Publication: April 1, 2020

2019

Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data

Maureen Watt and Scott Milligan

DOI: 10.1182/blood-2019-124101

Poster Presented at: The American Society of Hematology (ASH)

Conference dates: December 7, 2019 - December 10, 2019

A Retrospective, Observational Study Using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States